Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Lee's Pharma In-Licenses GI-Protective Aspirin

publication date: Apr 10, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Lee's Pharma of Hong Kong has in-licensed the China rights to a gastrointestinal-protective form of aspirin from PLx Pharma Inc, a Houston startup. PL2200 is a development-stage aspirin that is aimed at the cardiovascular market. Lee's Pharma develops its own drugs and also in-licenses western products for sale to the China market. More details....

Stock Symbol:  (HK: 950)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...